Safer and better performing bone graft substitute
26.11.2023 BBS-Bioactive Bone Substitutes Plc has received new subscription undertakings and supplements the Investor Memorandum dated 24th of November 2023 relating to the rights offering and publishes updated Basic Information Document
25.11.2023 BBS-Bioactive Bone Substitutes: The Notified Body has approved the Company’s quality system
24.11.2023 BBS-Bioactive Bone Substitutes Plc publishes the Investor Memorandum and the Basic Information Document related to the Offering and information regarding Subscription undertakings
Full preclinical safety and performance package as a medical device
Almost 3 million bone graft operations annually worldwide